Novacyt (LSE:NCYT), the France-based molecular diagnostics specialist, reported first-half 2026 revenue of £11.6 million, representing an 18% increase compared with the same period last year.
The company’s instrumentation business achieved around 30% year-on-year growth, supported by increasing customer adoption of its LightBench Discover platform. Meanwhile, the clinical diagnostics division expanded by more than 20%, driven by continued demand for its non-invasive prenatal testing solutions and sickle cell disease product portfolio.
Southern Cross Diagnostics, which Novacyt acquired in March, contributed £1.8 million in revenue during the period, providing an additional boost to the group’s overall performance.
Geographically, the company delivered solid growth across both the Americas and Asia-Pacific. Revenue in the Americas increased by more than 30%, while Asia-Pacific recorded growth of approximately 22%, with both regions benefiting from stronger instrument sales and continued demand for reproductive health products.
Novacyt is also progressing with its restructuring programme, which is expected to generate up to £4.0 million in annualised cost savings. In addition, the company anticipates receiving IVDR accreditation for its DPYD kit over the coming months, supporting the continued expansion of its diagnostics portfolio.
Leave a Reply